OSAP vs. BJDX, RSLS, DYNT, NMRD, INVO, SINT, QNRX, OSA, MOTS, and TNON
Should you be buying ProSomnus stock or one of its competitors? The main competitors of ProSomnus include Bluejay Diagnostics (BJDX), ReShape Lifesciences (RSLS), Dynatronics (DYNT), Nemaura Medical (NMRD), INVO Bioscience (INVO), Sintx Technologies (SINT), Quoin Pharmaceuticals (QNRX), ProSomnus (OSA), Motus GI (MOTS), and Tenon Medical (TNON). These companies are all part of the "surgical & medical instruments" industry.
Bluejay Diagnostics (NASDAQ:BJDX) and ProSomnus (NASDAQ:OSAP) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, community ranking, risk, analyst recommendations and media sentiment.
18.5% of Bluejay Diagnostics shares are owned by institutional investors. Comparatively, 70.0% of ProSomnus shares are owned by institutional investors. 17.6% of Bluejay Diagnostics shares are owned by insiders. Comparatively, 7.7% of ProSomnus shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Bluejay Diagnostics received 2 more outperform votes than ProSomnus when rated by MarketBeat users.
Bluejay Diagnostics has higher earnings, but lower revenue than ProSomnus. Bluejay Diagnostics is trading at a lower price-to-earnings ratio than ProSomnus, indicating that it is currently the more affordable of the two stocks.
Bluejay Diagnostics has a net margin of 0.00% compared to Bluejay Diagnostics' net margin of -87.14%. Bluejay Diagnostics' return on equity of 0.00% beat ProSomnus' return on equity.
In the previous week, ProSomnus had 2 more articles in the media than Bluejay Diagnostics. MarketBeat recorded 2 mentions for ProSomnus and 0 mentions for Bluejay Diagnostics. ProSomnus' average media sentiment score of 0.62 beat Bluejay Diagnostics' score of 0.00 indicating that Bluejay Diagnostics is being referred to more favorably in the media.
Bluejay Diagnostics has a beta of 0.98, indicating that its stock price is 2% less volatile than the S&P 500. Comparatively, ProSomnus has a beta of 0.6, indicating that its stock price is 40% less volatile than the S&P 500.
Summary
Bluejay Diagnostics and ProSomnus tied by winning 7 of the 14 factors compared between the two stocks.
Get ProSomnus News Delivered to You Automatically
Sign up to receive the latest news and ratings for OSAP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OSAP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ProSomnus Competitors List
Related Companies and Tools
